+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies

Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies

Pharmacology and Therapeutics 157: 120-124

In the era of personalized medicine detection of the molecular drivers of tumors and of specific DNA mutations predicting response or resistance to targeted agents has become routine practice in clinical oncology. The tumor biopsy depicts only a single timeframe from a single site, and might be inadequate to characterize a tumor because of intratumoral and intermetastatic heterogeneity. Circulating tumor DNA offers a "real time" tool for serially monitoring tumor genomes in a non-invasive manner providing accessible genetic biomarkers for cancer diagnosis, prognosis, and response to therapy. The liquid biopsy can be used for a variety of clinical and investigational applications. Future development will have to provide a cost effective analysis mainly identifying the genes known to be recurrently mutated in each tumor. Therefore, developing standardized methodologies for DNA analyses and validation in large prospective clinical studies is mandatory to implement the 'liquid biopsy' approach in the clinical management of cancer patients. In our review, we will focus on the clinical applications of liquid biopsies and on the recent findings in this field.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058222911

Download citation: RISBibTeXText

PMID: 26615782

DOI: 10.1016/j.pharmthera.2015.11.007

Related references

Tumor-derived exosomes in ovarian cancer - liquid biopsies for early detection and real-time monitoring of cancer progression. Oncotarget 8(61): 104687-104703, 2017

Gastrointestinal stromal tumors A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?. Asia-Pacific Journal of Clinical Oncology 4(4): 185-187, 2008

Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. Cold Spring Harbor Perspectives in Medicine 7(2), 2016

New generations of targeted therapies fighting the resistance in solid tumors. Current Opinion in Oncology 27(3): 243-249, 2016

Understanding and treating solid tumor-related disseminated intravascular coagulation in the "era" of targeted cancer therapies. Sage Open Medicine 5: 2050312117749133, 2018

Tissue requirements in lung cancer diagnosis for tumor heterogeneity, mutational analysis and targeted therapies: initial experience with intra-operative Frozen Section Evaluation (FROSE) in bronchoscopic biopsies. Journal of Thoracic Disease 8(Suppl 6): S488-S493, 2016

Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatric Blood & Cancer 2019: E27595-E27595, 2019

Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?. Current Opinion in Oncology 27(6): 560-567, 2016

Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors. Bulletin of Mathematical Biology 77(1): 1-22, 2016

A Sample-to-Targeted Gene Analysis Biochip for Nanofluidic Manipulation of Solid-Phase Circulating Tumor Nucleic Acid Amplification in Liquid Biopsies. Acs Sensors 2018, 2018

Real time, noninvasive imaging and quantitation of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors. Molecular Pharmaceutics 6(6): 1868-1875, 2010

Real time monitoring of the cell viability during treatment with tumor-targeted toxins and saponins using impedance measurement. Biosensors and Bioelectronics 35(1): 503-506, 2012

Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions. Plos One 9(8): E102452, 2015

Low-Temperature EPR Spectroscopy as a Probe-Free Technique for Monitoring Oxidants Formed in Tumor Cells and Tissues: Implications in Drug Resistance and OXPHOS-Targeted Therapies. Cell Biochemistry and Biophysics 2018, 2018

Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report. Journal of Clinical Pathology 71(8): 754-756, 2018